November 17th, 2009|

Launches RECOMBINATE a genetically engineered, non-plasma-derived FVIII bringing advanced care to people with Hemophilia in India. Baxter India Private Limited, a wholly owned subsidiary of Baxter International Inc., the global leader in Hemophilia care today announced the launch of RECOMBINATE in India. RECOMBINATE, a genetically engineered non plasma-derived recombinant factor (rFVIII) through increased viral safety and uninterrupted supply, represents a significant step forward in raising the standards of care for people with Hemophilia in India. RECOMBINATE is indicated for the prevention and control of hemorrhagic episodes and for the preoperative management of people with Hemophilia A.   

BioInvent inks licensing pact with Daiichi Sankyo to discover & develop therapeutic antibodies

November 16th, 2009|

BioInvent International AB has entered into a licence and discovery agreement with Daiichi Sankyo Company, Limited for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration, Daiichi Sankyo will be granted broad access to BioInvent's discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.

Novartis announces USD 1 billion investment to build largest pharmaceutical R and D institute in Chi

November 2nd, 2009|

Novartis announced today a USD 1 billion investment over the next five years, increasing R&D activities in China and confirming Novartis' long term commitment to China's further economic development, health reform and improving the health care of the Chinese people. The Novartis investment will include a significant expansion of The Novartis Institute of Biomedical Research (CNIBR) in Shanghai.

India is growth tonic for mid-tier global pharma

November 1st, 2009|

Two months ago, Michigan-based Perrigo Company, one of the world's largest over-the-counter (OTC) pharmaceutical producers with over $2 billion sales, acquired 85 per cent in Mumbai-based Vedants Drugs and Fine Chemicals for nearly Rs 60 crore.

Pharma Dept moots a string of measures to boost research in pharma industry

October 28th, 2009|

Pharmaceutical Department has recommended to the Department of Revenue a number of measures including hiking the benefit of weighted exemption to companies engaged in research and development with a view to scale up their overall spending in research activities in the country.

Sanofi-aventis sees new opportunities in Quebec

October 22nd, 2009|

A North American reorganization at pharmaceutical company Sanofi-aventis could provide its manufacturing operations in Laval with new opportunities.

Pharma enters emerging markets via generics

October 7th, 2009|

Major pharmaceutical companies see generics as a bridge to the futureMOST PHARMACEUTICAL innovators treat patent expiry like a terminal disease and the generics business as a sort of hospice where dying products ease into commodity oblivion, but recent deals and acquisitions suggest growing faith in an afterlife of emerging markets.

Drug MNCs look at India as a market

October 6th, 2009|

The list of drug majors scouting for a suitable buy in India is long. But this time, the attraction is: India as a market, and not merely as an inexpensive destination to source and produce products, say consultants and lawyers observing the increased merger and acquisition (M&A) activity seen in the pharmaceutical space.

Indias genetic divide may hit pharma cos R and D plans

September 29th, 2009|

Global pharma firms making drugs for the Indian market may have to review their discovery and development programme, following a path-breaking discovery by top Indian and American scientists that India is genetically not a single large population.

Wockhardt is top Indian pharma patentee bags government award

September 28th, 2009|

Pharmaceutical and biotechnology major Wockhardt Limited has received the Government of India award for the maximum number of patents filed and granted in India by any pharmaceutical company.

North Indian Pharma: Focusing on R and D and Tie-ups to Meet Challenging conditions

August 24th, 2009|

The North India based listed pharmaceutical companies have established strong presence in the domestic market, highly regulated markets and emerging markets during the last couple of years with several US FDA approved facilities, high-tech R&D laboratories, focus on new lifestyle drugs and partnership with international giants.

Race for a H1N1 Swine Flu Vaccine

August 24th, 2009|

MORE than two dozen pharmaceutical companies are racing against the clock to test, produce and ship more than a billion doses of swine flu vaccines to anxious populations worldwide.

Pharma Giant Roche To Strengthen R and D Pipeline In Israel Through Pontifax Deal

August 24th, 2009|

Swiss pharmaceutical giant F. Hoffmann–La Roche signed a deal with Israeli venture capital firm Pontifax Management Company for its first significant undertaking in the country to build up its R&D pipeline by way of investment in the Israeli life science industry.

Fortis inks Wockhardt deal

August 24th, 2009|

Delhi-based hospital chain Fortis Healthcare has acquired 10 hospitals from the Wockhardt stable for Rs 909 crore.

Lilly Reports on Outcome of Phase III Study of Arzoxifene

August 18th, 2009|

x (NYSE: LLY) announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women.

Big pharma companies join outsourcing queue

August 18th, 2009|

India emerging as a big global destination for contract manufacturing, unlike R&D outsourcing

Low costs a draw for foreign drug makers

August 10th, 2009|

Low costs, high technical capabilities and a skilled work force are making India an attractive destination for research and contract manufacturing of drugs

Pharma sector in for an R and D boost from govt

August 10th, 2009|

The pharmaceutical industry in India is likely to see added stimulus in coming months. The department of pharmaceuticals (DoP) has put forth a number of proposals to the government which will help boost the pharma sector in the country, said Ashok Kumar, secretary of DoP, on Saturday at the AGM of the Organisation of Pharmaceutical Producers of India (OPPI).

Indias drug discovery efforts suffer failing health

August 2nd, 2009|

The next two or three weeks will be crucial for Glenmark Pharmaceuticals’, and India’s, dreams of developing an original blockbuster pharmaceutical drug.

Pandemic flu shows need for pharma incentives WHO

July 14th, 2009|

Pharmaceutical firms need incentives, including lucrative patents, to keep creating drugs and vaccines against emergent threats such as the H1N1 influenza pandemic, the World Health Organisation's head said on Tuesday.